Chronic Kidney Disease and High Blood Pressure Study
NOW RECRUITING
-
Adelaide SA | Goolwa SA
A study to assess the effectiveness of a new medication in combinatinon with Dapagliflozin (a currently available medication) in people with Chronic Kidney Disease and High Blood Pressure.
- Age > 18 years
- Reduced kidney function (assesed by a blood test at screening)
- Taking regular blood pressure medication
- Blood pressure remains high despite medication
Outpatient Visit
- Clinic visits at weeks 2, 4, 8, 16, and 35
- Then every 4 months thereafter
Payment / Remuneration
- Reimbursed for travel $75 per clinic visit
Information for Practitioners
- Screening bloods
- Kidney failure with elevated UACR - assessed during screening visit
- Stable dose of ACE or ARB
- Able to tolerate Empagliflozin (does not have to be already taking)
- SBP ≥130mmHg - Exclusion SBP >180mmHg
- Exclusion - Known hyperkalaemia >5.5mmol/L
- Exclusion - Type 1 diabetes
- Exclusion - CVA, MI or worsening HF 3 months prior to randomisation